The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer
-
Published:2019-06
Issue:3
Volume:153
Page:535-540
-
ISSN:0090-8258
-
Container-title:Gynecologic Oncology
-
language:en
-
Short-container-title:Gynecologic Oncology
Author:
Pignata Sandro, Scambia Giovanni, Lorusso Domenica, De Giorgi Ugo, Nicoletto Maria Ornella, Lauria Rossella, Mosconi Anna Maria, Sacco Cosimo, Omarini Claudia, Tagliaferri Pierosandro, Ferrandina GabriellaORCID, Cinieri Saverio, Savarese Antonella, Valabrega Giorgio, Pisano Carmela, Salutari Vanda, Raspagliesi Francesco, Kopf Barbara, Cecere Sabrina Chiara, Amadio Giulia, Maltese Giuseppa, Di Napoli Marilena, Greggi Stefano, Signoriello Simona, Daniele Gennaro, Sacco Alessandra, Losito Simona, Normanno Nicola, Perrone FrancescoORCID, Gallo Ciro, Piccirillo Maria CarmelaORCID
Subject
Obstetrics and Gynecology,Oncology
Reference23 articles.
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136:E359–86. 2. Fuchs I, Vorsteher N, Buhler H, Evers K, Sehouli J, Schaller G, et al. The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma. Anticancer Res.. 2007;27:959–63. 3. Bellone S, Frera G, Landolfi G, Romani C, Bandiera E, Tognon G, et al. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol. Oncol.. 2007;106:513–20. 4. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med.. 2007;357:2040–8. 5. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.. 2011;29:2011–9.
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|